Dr. Paul R. Eisenberg is Senior Vice President, U.S. Medical. Before assuming this role, Eisenberg was Senior Vice President, Global Medical and Chief Medical Officer, overseeing global medical and scientific affairs. Dr. Eisenberg joined Amgen in 2005 as Vice President of Global Safety and was subsequently promoted to Senior Vice President of Global Regulatory Affairs and Safety. In 2014 assumed responsibility for Amgen’s Global Medical Affairs organization and appointed Chief Medical Officer.   Prior to Amgen, Dr. Eisenberg held several leadership roles at Lilly R&D in the cardiovascular, critical care, and inflammation therapeutic areas, in cardiovascular research and clinical investigation, and in global product safety.   Dr. Eisenberg received his M.D. from New York Medical College and a MPH & Tropical Medicine degree from the Tulane School of Public Health. He was Professor of Medicine at Washington University in St. Louis and Director of Cardiac Intensive Care at Barnes Hospital. During his 18-year academic career his research focused on cardiovascular disease and thrombosis.   Dr. Eisenberg has led the development and registration of multiple New Molecular Entities (NMEs) in cardiovascular and critical care, and the global registration of all Amgen products from 2007 to 2014.

 R&D